Find cancer clinical trials
Search by cancer, biomarker, treatment, country, and status. Public ClinicalTrials.gov registry data retrieved 2026-09-10.
139 of 139 studies
NCT04181060Phase 3
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Lung Cancer | biomarker: EGFR | Targeted therapy
United States603 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT04181060Not verified
NCT06106802Phase 2
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Lung Cancer | biomarker: EGFR, MET | Targeted therapy
South Korea1 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT06106802Not verified
NCT06203600Phase 2 / Phase 3
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Stomach Cancer | biomarker: PD-L1 | Immunotherapy, Targeted therapy, Chemotherapy
United States374 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT06203600Not verified
NCT06293898Phase 1
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Stomach Cancer | biomarker: HER2
United States26 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT06293898Not verified
NCT06452277Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Lung Cancer | biomarker: HER2 | Immunotherapy, Chemotherapy
United States, Argentina, Australia +33279 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT06452277Not verified
NCT06830694Phase 2
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Lung Cancer | biomarker: EGFR | Immunotherapy, Chemotherapy
South Korea1 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT06830694Not verified
NCT07308132Phase 1
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Lymphoma | biomarker: CD20 | Immunotherapy, Chemotherapy
Australia, Belgium, France +219 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT07308132Not verified
NCT07462377Phase 1
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Lung Cancer | biomarker: EGFR
United States6 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT07462377Not verified
NCT07640789Phase 3
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
Lung Cancer | biomarker: EGFR | Targeted therapy, Radiotherapy, Chemotherapy
China1 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT07640789Not verified
NCT07659782Phase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Lung Cancer | biomarker: KRAS | Targeted therapy
United States, Australia12 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT07659782Not verified
NCT04928846Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer | biomarker: EGFR, MET | Chemotherapy
United States, Argentina, Australia +29317 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT04928846Not verified
NCT06253871Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Lung Cancer, Stomach Cancer | biomarker: HER2
United States, France, Ireland +553 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT06253871Not verified
Five statuses, five different questions
- • Registry status: whether the study is listed as recruiting.
- • Site status: whether we have verified the location.
- • International access: whether patients from abroad may be accepted.
- • Verification: how recently we checked this record.
- • Patient match: an initial screen, not an eligibility decision.
Not sure where to start?
Upload a report summary so the team can review a potential match before you contact a study site.
Source: public ClinicalTrials.gov registry, retrieved 2026-09-10. International patient access and site readiness have not been verified for any listed study and are shown as unknown on each result. View sources and editorial policy.